Market Trends of Global Lipid Regulators Industry
The Branded Statins Segment is Expected to Witness Considerable Growth Over the Forecast Period
Branded statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentrations. Some of the statins available in the market include atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin. These branded statins are majorly used for treating dyslipidemia. Dyslipidemia, defined as elevated total or low-density lipoprotein (LDL) cholesterol levels or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for coronary heart disease (CHD) and stroke.
The increasing diabetic population is expected to propel the segment growth as the diabetic population is prone to a higher incidence of dyslipidemia. For instance, as per the World Health Organization, there are over 400.0 million people with diabetes across the world, and its treatment constitutes around 12.0% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and affected millions worldwide. Currently, about 10% of all diabetes cases are type 1, and the remaining are type 2. The statins competitively inhibit HMG-CoA reductase and lower lipid levels in diseased populations.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to witness significant growth over the forecast period. The growth is due to factors such as increasing obesity, diabetes, and product launches by the key players. For instance, according to OECD data published in May 2021, the North American countries of the United States and Mexico have one of the highest prevalences of obesity and diabetes in the world. Moreover, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, the demand for lipid regulators is expected to increase over the forecast period. For instance, as per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) data updated in December 2021, more than 34.2 million people had diabetes (or 10.5% of the United States population). The same source also stated that an estimated 26.9 million people of all ages had been diagnosed with diabetes (8.2% of the United States population). Of the people diagnosed with diabetes, 210,000 are children and adolescents younger than 20, including 187,000 with type 1 diabetes.
Key product launches, high concentration of market players or manufacturers' presence, acquisitions and partnerships among major players, and increasing cases of obesity in the United States are some of the factors driving the growth of the lipid regulators market in the country. For instance, according to CDC data updated in May 2022, more than 41.9% of Americans were obese. The prevalence of obesity in the United States increased from 30.5 to 41.9%. The prevalence of severe obesity rose from 4.7% to 9.2% during the same period. The CDC has identified obesity as the leading cause of preventable death in the United States, and it is one of the leading causes of chronic diseases both worldwide and in the United States. Obesity-related disorders, known as comorbidities, include cardiovascular diseases and some cancers. Increasing obesity requires cholesterol control, wherein lipid regulators come into play, which is expected to boost market growth over the forecast period in the United States.
